Expertise in
6
conditions

I-chang C. Hsieh

Linkou Branch, 
Taoyuan, TNQ, TW 
Expertise in
6
conditions
Linkou Branch, 
Taoyuan, TNQ, TW 

Overview

I-chang Hsieh practices practicing medicine in Taoyuan, Taiwan.

Hsieh is highly rated in 6 conditions, according to our data. Their clinical expertise encompasses Heart Attack, Acute Coronary Syndrome, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Angioplasty.

They are actively involved in clinical research, co-authoring 172 peer reviewed articles and participating in 3 clinical trials.

Locations

Linkou Branch, Taoyuan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
XIENCE 28 Global Study
XIENCE 28 Global Study
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug, Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

172 Total Publications

Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study).
Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study).
Journal: Journal of the American Heart Association
Published: May 14, 2026

Frequently Asked Questions about I-chang C. Hsieh

Is I-chang C. Hsieh a top-rated expert for Heart Attack?

MediFind is an objective health platform that identifies experts based on real-world data. I-chang C. Hsieh is classified as an Advanced expert for Heart Attack, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does I-chang C. Hsieh participate in research or clinical trials?

Yes. I-chang C. Hsieh has published 172 articles and abstracts on conditions like Heart Attack. You can view a list of I-chang C. Hsieh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsieh's expertise for a condition
ConditionClose
      View All 42 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile